Get the Stockscreener App
55.31
1.60%
0.87
After Hours:
55.31
Corcept Therapeutics Inc stock is traded at $55.31, with a volume of 650.86K.
It is up +1.60% in the last 24 hours and up +0.31% over the past month.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
See More
Previous Close:
$54.44
Open:
$54.93
24h Volume:
650.86K
Relative Volume:
0.73
Market Cap:
$5.80B
Revenue:
$628.56M
Net Income/Loss:
$141.82M
P/E Ratio:
43.90
EPS:
1.26
Net Cash Flow:
$142.60M
1W Performance:
+10.95%
1M Performance:
+0.31%
6M Performance:
+66.40%
1Y Performance:
+122.84%
1-Day Range:
$53.76
$55.36
1-Week Range:
$49.00
$55.36
52-Week Range:
$20.84
$62.22
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650.688.8803
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
55.31 | 5.80B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-23 | Upgrade | Truist | Hold → Buy |
| Apr-11-23 | Initiated | SVB Securities | Market Perform |
| Apr-04-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-22 | Downgrade | Truist | Buy → Hold |
| Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
| Jun-27-22 | Resumed | Canaccord Genuity | Buy |
| Feb-02-22 | Initiated | Canaccord Genuity | Buy |
| Jan-28-22 | Initiated | Truist | Buy |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-19 | Initiated | Jefferies | Buy |
| Sep-06-19 | Initiated | H.C. Wainwright | Buy |
| Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-10-18 | Reiterated | Stifel | Hold |
| May-31-18 | Downgrade | Stifel | Buy → Hold |
| Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Aug-31-17 | Initiated | Stifel | Buy |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-21-15 | Initiated | FBR Capital | Outperform |
| Jan-13-14 | Downgrade | Stifel | Buy → Hold |
| Aug-09-13 | Downgrade | Janney | Buy → Neutral |
| Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
| Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
Here’s Why Analysts Are Bullish on Corcept Therapeutics Incorporated (CORT) - Insider Monkey
Ovarian Cancer Drugs Market Analysis: Segments, Drivers, - openPR
Here's What Could Help Corcept (CORT) Maintain Its Recent Price Strength - MSN
Corcept Therapeutics Incorporated (CORT): Why Should You Buy This Growth Stock For The Next 5 Years? - Yahoo Finance
Hennion & Walsh Asset Management Inc. Trims Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Burney Co. Increases Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Sells $111,188.00 in Stock - MarketBeat
Corcept Therapeutics director Daniel Swisher sells $111,188 in stock By Investing.com - Investing.com Canada
Corcept Submits Application for Another Cushing's Syndrome Drug - MSN
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
Cushings Syndrome Market Is Booming Worldwide 2024-2031 | Corcept Therapeutics Inc., HRA Pharma - EIN News
Range Financial Group LLC Buys New Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Incorporated (CORT) Surged on Strong Results and Increased Guidance - Yahoo Finance
Corcept Therapeutics officer sells shares for $251,950 - Investing.com India
Corcept Therapeutics officer sells shares for $251,950 By Investing.com - Investing.com Australia
Sean Maduck Sells 20,000 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock - MarketBeat
Corcept Therapeutics' chief business officer sells shares worth $555,551 By Investing.com - Investing.com Nigeria
Corcept Therapeutics' chief business officer sells shares worth $555,551 - Investing.com
Corcept Therapeutics president sells $1 million in stock By Investing.com - Investing.com Canada
Corcept asks FDA to OK relacorilant for Cushing’s syndrome - Cushing's Disease News
Analysts Set Corcept Therapeutics Incorporated (NASDAQ:CORT) Target Price at $65.25 - MarketBeat
Here's Why Corcept Therapeutics (NASDAQ:CORT) Has Caught The Eye Of Investors - Simply Wall St
Corcept files NDA for new Cushing's syndrome drug By Investing.com - Investing.com Canada
Corcept Therapeutics Submits New Drug Application for Cushing's Sydrome Treatment - MarketWatch
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism - Business Wire
Corcept Therapeutics Submits FDA Application for Breakthrough Cushing's Syndrome Treatment Relacorilant - StockTitan
Principal Financial Group Inc. Lowers Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Will Corcept Therapeutics Incorporated (CORT) Make You Rich In 2025? - Yahoo Finance
10 Stocks That Will Make You Rich In 2025 - Insider Monkey
Hypercortisolism research fuels Corcept’s DTC awareness campaign - MM+M Online
What is Zacks Research's Forecast for CORT FY2025 Earnings? - MarketBeat
Abortion Drugs Market Growth in Future Scope 2024-2031 | Corcept - openPR
Zacks Research Issues Negative Forecast for CORT Earnings - MarketBeat
Geode Capital Management LLC Grows Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
World Investment Advisors LLC Takes Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept’s dazucorilant fails to slow ALS progression in clinical trial - ALS News Today
Corcept Therapeutics’ Cushing’s syndrome therapy shows promise in Phase III trial - Yahoo Finance
Corcept Therapeutics Incorporated (NASDAQ:CORT) Short Interest Down 7.0% in November - MarketBeat
Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism - BioSpace
Relacorilant shows promise in long-term hypercortisolism study - Investing.com
Corcept's Phase 3 Study Shows Breakthrough Blood Pressure Results for Relacorilant in Long-term Treatment - StockTitan
Stifel Financial Corp Buys 20,546 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Shares Rise More Than 60% in Three Months: Here's Why - MSN
State Street Corp Has $162.87 Million Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study - MSN
Community Spotlight: Breakthrough Type 1 Diabetes Walk - AOL
Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes - Yahoo Finance
Korlym shows promise in Cushing's syndrome study By Investing.com - Investing.com Canada
Verition Fund Management LLC Sells 28,931 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes - BioSpace
Corcept Therapeutics Diabetes Drug Korlym Meets Primary Endpoint in Study - MarketWatch
Corcept Therapeutics Inc Stock (CORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):